Surround optical fiber immunoassay (SOFIA): An ultra-sensitive assay for prion protein detection

Chang, Binggong; Gray, P. C.; Piltch, Martin S; Bulgin, Marie S.; Sorensen-Melson, Sharon; Miller, Michael W.; Davies, Paul; Brown, David R.; Coughlin, Daniel R.; Rubenstein, Richard

doi:10.1016/j.jviromet.2009.02.019

Cited by 34 publications

(26 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1,[44][45][46] Because newly acquired anti-GFAP antibody response usually takes about 5 days to manifest, 26,47,48 it is unlikely that the acute post-TBI autoantibody levels we report here were from a de novo response to current TBI, but rather to a sustained increase because of previous head injuries. At present, however, we cannot rule out whether the acute TBI event might serve to be an antigen-boosting event for those with pre-existing anti-GFAP antibody titers.…”

Section: Discussionmentioning

confidence: 90%

Plasma Anti-Glial Fibrillary Acidic Protein Autoantibody Levels during the Acute and Chronic Phases of Traumatic Brain Injury: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot Study

Wang

Yang

Yue

et al. 2016

Journal of Neurotrauma

View full text Add to dashboard Cite

We described recently a subacute serum autoantibody response toward glial fibrillary acidic protein (GFAP) and its breakdown products 5-10 days after severe traumatic brain injury (TBI). Here, we expanded our anti-GFAP autoantibody (AutoAb[GFAP]) investigation to the multicenter observational study Transforming Research and Clinical Knowledge in TBI Pilot (TRACK-TBI Pilot) to cover the full spectrum of TBI (Glasgow Coma Scale 3-15) by using acute (<24 h) plasma samples from 196 patients with acute TBI admitted to three Level I trauma centers, and a second cohort of 21 participants with chronic TBI admitted to inpatient TBI rehabilitation. We find that acute patients self-reporting previous TBI with loss of consciousness (LOC) (n = 43) had higher day 1 AutoAb[GFAP] (mean -standard error: 9.11 -1.42; n = 43) than healthy controls (2.90 -0.92; n = 16; p = 0.032) and acute patients reporting no previous TBI (2.97 -0.37; n = 106; p < 0.001), but not acute patients reporting previous TBI without LOC (8.01 -1.80; n = 47; p = 0.906). These data suggest that while exposure to TBI may trigger the AutoAb[GFAP] response, circulating antibodies are elevated specifically in acute TBI patients with a history of TBI. AutoAb[GFAP] levels for participants with chronic TBI (average post-TBI time 176 days or 6.21 months) were also significantly higher (15.08 -2.82; n = 21) than healthy controls ( p < 0.001). These data suggest a persistent upregulation of the autoimmune response to specific brain antigen(s) in the subacute to chronic phase after TBI, as well as after repeated TBI insults. Hence, AutoAb[GFAP] may be a sensitive assay to study the dynamic interactions between postinjury brain and patient-specific autoimmune responses across acute and chronic settings after TBI.

show abstract

Section: Discussionmentioning

confidence: 90%

Plasma Anti-Glial Fibrillary Acidic Protein Autoantibody Levels during the Acute and Chronic Phases of Traumatic Brain Injury: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot Study

Wang

Yang

Yue

et al. 2016

Journal of Neurotrauma

View full text Add to dashboard Cite

show abstract

“…50 For direct EIMAF, tissue homogenates or biofluids were added to the capture Ab followed by the biotinylated detection Mab DA9. Following a 1 h incubation, streptavidin conjugated to Rhodamine Red X (1:1000; Invitrogen, Norwalk, CT) was added and incubated for 1 h. The wells were washed with TBS containing Tween-20, treated with NaOH and neutralized.…”

Section: Eimaf and A-eimafmentioning

confidence: 99%

“…49 We previously described the development of an assay termed SOFIA (surround optical fiber immunoassay) for the detection of the abnormal prion protein in prion diseased animals and humans. [50][51][52][53][54] As a result of our continued efforts to develop advanced biomarker assay technologies from readily accessible samples, we have changed the term SOFIA to EIMAF (enhanced immunoassay using multi-arrayed fiberoptics).…”

Section: Introductionmentioning

confidence: 99%

A Novel, Ultrasensitive Assay for Tau: Potential for Assessing Traumatic Brain Injury in Tissues and Biofluids

Rubenstein

Chang

Davies

et al. 2015

Journal of Neurotrauma

Self Cite

View full text Add to dashboard Cite

Traumatic brain injury (TBI) is a cause of death and disability and can lead to tauopathy-related dementia at an early age. Pathologically, TBI results in axonal injury that is coupled to tau hyperphosphorylation, leading to microtubule instability and tau-mediated neurodegeneration. This suggests that the forms of this protein might serve as neuroinjury-related biomarkers for diagnosis of injury severity and prognosis of the neurological damage prior to clinical expression. We initially determined whether we could detect tau in body fluids using a highly sensitive assay. We used a novel immunoassay, enhanced immunoassay using multi-arrayed fiberoptics (EIMAF) either alone or in combination with rolling circle amplification (a-EIMAF) for the detection of total (T) and phosphorylated (P) tau proteins from brains and biofluids (blood, CSF) of rodents following controlled cortical impact (CCI) and human patients post severe TBI (sTBI). This assay technology for tau is the most sensitive to date with a detection limit of approximately 100 ag/mL for either T-tau and Ptau. In the rodent models, T-tau and P-tau levels in brain and blood increased following CCI during the acute phase and remained high during the chronic phase (30 d). In human CSF samples, T-tau and P-tau increased during the sampling period (5-6 d). T-tau and P-tau in human serum rose during the acute phase and decreased during the chronic stage but was still detectable beyond six months post sTBI. Thus, EIMAF has the potential for assessing both the severity of the proximal injury and the prognosis using easily accessible samples.

show abstract

“…PrP Sc was detected in a proportion of the PMCA reactions seeded with samples from infected rams using an enhanced sensitivity immunoassay (Surround optical fiber immunoassay, SOFIA (Chang et al, 2009)). …”

Section: Rubenstein Et Al (2012) Prp Sc Detection and Infectivity Imentioning

confidence: 99%

Scientific Opinion on the risk of transmission of classical scrapie via in vivo derived embryo transfer in ovine animals

Publication¹

2013

EFS2

View full text Add to dashboard Cite

European Food Safety Authority (EFSA), Parma, Italy ABSTRACTThe risk of transmission of classical scrapie via the transfer of in vivo derived embryo in ovines was assessed, taking into account the scientific information made available since the last EFSA opinion on this topic (2010) (see http://www.efsa.europa.eu/en/efsajournal/pub/1429.htm). The potential impact of PrP genotype of the embryo and/or of the ram and donor ewe on this risk was also assessed. The new data made available over the last three years further reinforce the view that classical scrapie could be vertically transmitted in sheep. Since the possibility of such vertical transmission was already considered in the previous opinion, its conclusions and recommendations relating to the risk of classical scrapie transmission via embryo transfer remain valid. In ovines, the susceptibility to classical scrapie infection in sheep is strongly influenced by certain polymorphisms of the PrP gene. Under natural exposure conditions, animals that are heterozygous or homozygous A 136 R 154 R 171 display respectively a low or negligible risk of being infected. The genetic control of the susceptibility to classical scrapie is also likely to impact on the risk of transmitting the disease via embryo transfer. Irrespective of the embryo's genotype, embryos derived from rams and dams carrying at least one ARR allele would significantly decrease this risk (compared to an embryo from parents of unknown genotypes). The use of homozygous ARR embryos would provide the highest level of safety regarding the risk of transmitting classical scrapie through embryo transfer (in vivo derived embryos). The use of heterozygous ARR embryos would ensure a higher level of safety compared to Q 171 /Q 171 embryos. Finally, it was concluded that, providing the OIE recommendations and procedures relating to embryo transfer are adhered to, the risk of transmitting classical scrapie due to the transfer of homozygous or heterozygous ovine ARR embryos can be considered negligible. SUMMARYFollowing a request from the European Commission, the Panel on Biological Hazards (BIOHAZ) was asked to deliver a scientific opinion on the risk of transmission of classical scrapie via in vivo derived embryo transfer in ovine. The Panel was requested to provide an updated scientific opinion on the risk of transmission of classical scrapie via in vivo derived embryo transfer in ovine animals, taking into account any new scientific information made available since its last assessment on this issue in 2010 4 . In addition, the Panel was requested to elaborate on this risk of transmission according to the PrP genotype of the embryo and/or of the ram and donor ewe.The Panel reviewed the scientific literature published since the adoption of the previous Opinion covering this issue in 2010 and concluded that relevant findings available further reinforce the view that classical scrapie in small ruminants could be vertically transmitted. Since the possibility of vertical transmission was already considered in the pr...

show abstract

Surround optical fiber immunoassay (SOFIA): An ultra-sensitive assay for prion protein detection

Cited by 34 publications

References 53 publications

Plasma Anti-Glial Fibrillary Acidic Protein Autoantibody Levels during the Acute and Chronic Phases of Traumatic Brain Injury: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot Study

Plasma Anti-Glial Fibrillary Acidic Protein Autoantibody Levels during the Acute and Chronic Phases of Traumatic Brain Injury: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot Study

A Novel, Ultrasensitive Assay for Tau: Potential for Assessing Traumatic Brain Injury in Tissues and Biofluids

Scientific Opinion on the risk of transmission of classical scrapie via in vivo derived embryo transfer in ovine animals

Contact Info

Product

Resources

About